intoplicine

structure in first source

Also Known As:

11-(3-dimethylaminopropylamino)-3-hydroxy-8-methyl-7H-benzo(e)pyrido(4,3-b)indole dimethanesulfonate; NSC D645008; RP 60475F; RP60475F; intoplicin; 7H-Benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl-

Networked: 9 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - intoplicine: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - intoplicine: 9

Related Diseases

1.	Neoplasms (Cancer) 11/01/1999 - "Twenty-eight patients with refractory advanced malignancies who met standard phase I eligibility criteria were enrolled in a dose-escalation study of intoplicine, ranging from 7 to 420 mg/m2/day administered as a continuous 72 h i.v. infusion. " 11/01/1999 - "Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors." 01/01/1999 - "In the present phase I study, with the primary objective to determine the maximum tolerated dose, intoplicine was administered by a 24 h continuous infusion every 21 days to 32 patients with solid malignant tumors. " 01/05/1994 - "Activity was seen against breast (71%), non-small-cell lung (69%), and ovarian (45%) cancer colony-forming units at a intoplicine concentration of 10.0 micrograms/mL after 1-hour exposure. " 02/15/1997 - "Low light level fluorescence microscopy studies have been carried out on MCF7-P human mammary tumor cells to localize the intracellular distribution of two new anticancer drugs, Pazelliptine and Intoplicine, which are currently under clinical evaluation. "
2.	Colonic Neoplasms (Colon Cancer) 01/01/1994 - "In these phase I studies a number of marginal responses were noted with topotecan; partial and marginal responses, with CPT-11 (particularly in patients with colon cancer); and no response, with intoplicine. "
3.	Thrombocytopenia (Thrombopenia) 01/01/1994 - "The dose-limiting toxicities were different for all three of the agents, with neutropenia and thrombocytopenia being dose-limiting for topotecan; diarrhea, for CPT-11; and hepatotoxicity, for intoplicine. "
4.	Poisoning 10/01/1993 - "Hence, intoplicine might circumvent topoisomerase I-mediated and topoisomerase II-mediated resistance by poisoning both enzymes simultaneously."
5.	Neutropenia 01/01/1994 - "The dose-limiting toxicities were different for all three of the agents, with neutropenia and thrombocytopenia being dose-limiting for topotecan; diarrhea, for CPT-11; and hepatotoxicity, for intoplicine. "

Related Drugs and Biologics

1.	Type I DNA Topoisomerases (Topoisomerase I)
2.	intoplicine
3.	indole
4.	Topotecan (Hycamtin)
5.	Irinotecan (Camptosar)
6.	pazelliptine
7.	Type II DNA Topoisomerases (Topoisomerase II)
8.	DNA (Deoxyribonucleic Acid)
9.	Suspensions
10.	Enzymes